Dear Colleagues,

Immunotherapy has become a mainstay in the management of thoracic malignancies over the past decade. Moving from the initial phase III studies in last-line metastatic NSCLC to the adjuvant setting, immune checkpoint inhibitors and CTLA4 inhibitors have revolutionized the treatment of disease. Not only has immunotherapy integrated into all stages of management of NSCLC, its benefits are also seen across other thoracic pathologies, including SCLC and mesothelioma. While immunotherapy has been a welcome addition to the therapeutic tool kit for thoracic malignancies, challenges remain in understanding which patients are most likely or least likely to benefit from treatment. Furthermore, there are toxicities to consider with this therapeutic option, both clinically and financially.

For this Special Issue of Current Oncology, submissions that advance the literature on the use of immunotherapy in thoracic malignancies are sought. Although all manuscripts will be considered, priority will be given to manuscripts focusing on:

• Optimizing patient selection for different therapeutic options;
• Understanding risk factors for toxicity;
• Evaluating the cost and resource implications of immunotherapy;
• Understanding mechanisms of immunotherapy resistance and novel therapies to overcome resistance.

We look forward to receiving your contributions.

Dr. Cheryl Ho
Dr. Randeep Sangha
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• immunotherapy
• immune checkpoint inhibitors
• CTLA4 inhibitors
• predictive factors
• financial implications
• toxicity
• resistance